La marca ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN, fundada en 2010 (Estados Unidos de América), a 496 marcas hermanas y 17477 marcas de la competencia. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN es una marca de BRISTOL-MYERS SQUIBB COMPANY, que cotiza en la bolsa de valores de New York. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN pertenece al sector empresarial Fabricantes de medicamentos.

ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN es una marca comercial de BRISTOL-MYERS SQUIBB COMPANY (BMY) Cotización de la acción

Precio de la acción y rentabilidad de la acción BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)

Compre BRISTOL-MYERS SQUIBB COMPANY y comparta con
(0% comisión y acciones fraccionarias)
Su capital está sujeto a riesgo. Se aplican otras tarifas. Para obtener más información, visite etoro.com/trading/fees.

Simulador de inversión :

Cantidad invertida 44,21 USD

Valorización de su cartera
BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN) en 5 años* 40,83 USD

Historial de precios de acciones BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)